Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1985-7-18
|
pubmed:abstractText |
Thirty-eight Stage III ovarian carcinoma patients were treated with a combined modality protocol consisting of sequential initial surgery with a maximal tumor reduction, CHAD combination chemotherapy, second look reductive surgery and whole abdominal irradiation. Sixteen patients (42%) had minimal residual tumors (less than 2 cm) after initial surgery (Stage IIIA) and 22 (58%) had large residual tumors (greater than 2 cm) (Stage IIIB). The patients received 3-14 courses of CHAD combination chemotherapy, with a response rate (CR + PR) in the evaluable (Stage IIIB) patients of 91%. Twenty-eight patients had a second attempt of cytoreductive operation (10 Stage IIIA patients and 18 Stage IIIB patients). In 10 patients no residual tumor was found. In another 12 patients residual tumor (less than 2 cm) was found and completely resected, whereas in six patients a complete resection of large residual tumors (greater than 2 cm) was not possible. Twenty-one of the patients also completed a course of whole abdominal radiotherapy. Radiation was well-tolerated with the usual expected amounts of nausea, vomiting, diarrhea and transient leukopenia and thrombocytopenia. 11/21 (52%) of the patients relapsed within the first 18 months after completion of radiotherapy. The actuarial relapse-free survival at 36 months from completions of radiotherapy was 44%. The actuarial survival for the whole group from diagnosis was 43% at 3 years (70% for Stage IIIA and 41% for Stage IIIB). The data indicated that this combined modality protocol is both feasible and well-tolerated but its curative potential for patients with advanced ovarian carcinoma is as yet unknown.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0167-8140
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
237-44
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:2988025-Adenocarcinoma,
pubmed-meshheading:2988025-Adenocarcinoma, Mucinous,
pubmed-meshheading:2988025-Adult,
pubmed-meshheading:2988025-Aged,
pubmed-meshheading:2988025-Altretamine,
pubmed-meshheading:2988025-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2988025-Carcinoma,
pubmed-meshheading:2988025-Cisplatin,
pubmed-meshheading:2988025-Combined Modality Therapy,
pubmed-meshheading:2988025-Cyclophosphamide,
pubmed-meshheading:2988025-Doxorubicin,
pubmed-meshheading:2988025-Endometriosis,
pubmed-meshheading:2988025-Female,
pubmed-meshheading:2988025-Humans,
pubmed-meshheading:2988025-Middle Aged,
pubmed-meshheading:2988025-Ovarian Neoplasms
|
pubmed:year |
1985
|
pubmed:articleTitle |
Combined modality treatment for stage III ovarian carcinoma.
|
pubmed:publicationType |
Journal Article
|